Field Trip Health & Wellness Announces Posting on the OTC Market
Trading on the OTCQB Effective February 2, 2023, under the Symbol “FTHWF”TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip...
COVID-19
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3...
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full...
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first...
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development...
Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)Positive safety profile with 96.7% of...
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical...
Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status
Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not RecommendedSANTA...
Microbot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series
Dr. Giora Weisz, a Practicing Interventional Cardiologist and Clinical Researcher who was One of the Early Users of Robotic-Enhanced Coronary...
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such...
QHSLab, Inc. Reiterates its 2022 Projection of a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care
QHSLab reports that commercialization and the path to profitability is in clear sight, which is an unfamiliar acknowledgment for investors...
Junshi Biosciences Announces Approval for Marketing of VV116 in China
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader...
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
Commercial launch planned for February 20, 2023BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical...